Mihran Shirinian

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19

Roberto Caricchio, Antonio Abbate, Jamie Meng et al. · JAMA · 2021 · 166 citations · Full text

Medicine, Immunology, Pharmacotherapy +11

Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: The M. D. Anderson cancer center experience

Mihran Shirinian, Randal S. Weber, Scott M. Lippman et al. · Head & Neck · 1994 · 86 citations

Medicine, Oncology, Surgery +13

Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma.

Isaiah W. Dimery, S S Legha, Mihran Shirinian et al. · Journal of Clinical Oncology · 1990 · 83 citations

Medicine, Oncology, Cancer Drug Toxicity Management +12

Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy

Jin S. Lee, William K. Murphy, Mihran Shirinian et al. · Cancer Chemotherapy and Pharmacology · 1991 · 22 citations

Medicine, Pharmacology, Pharmacotherapy +10